Real-world pharmacovigilance study of FDA adverse event reporting system events for finerenone.

IF 3 3区 医学 Q2 PHARMACOLOGY & PHARMACY Expert Opinion on Drug Safety Pub Date : 2024-10-09 DOI:10.1080/14740338.2024.2412218
Youqi Huang, Hongjin Gao, Yuze Lin, Xiaowen Chen, Mingyu Chen, Min Chen
{"title":"Real-world pharmacovigilance study of FDA adverse event reporting system events for finerenone.","authors":"Youqi Huang, Hongjin Gao, Yuze Lin, Xiaowen Chen, Mingyu Chen, Min Chen","doi":"10.1080/14740338.2024.2412218","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>This study analyzed the signal mining of adverse events caused by finerenone based on the US Food and Drug Administration Adverse Event Reporting System (FAERS) and evaluated the drug's safety to provide a reference for the safe administration of this medication in medical institutions.</p><p><strong>Methods: </strong>FAERS data from the third quarter of 2021 to the fourth quarter of 2023 were used, and the adverse event codes of the Medical Dictionary for Regulatory Activities were compared. After the data were processed, adverse event reports that featured finerenone as the most suspected drug were extracted.</p><p><strong>Results: </strong>A total of 905 reported cases of adverse events including finerenone as the first suspected drug were extracted. The ratio of male to female patients was 1.25, and most were aged 65-85 years (30.1%). The adverse events that were reported more frequently with positive signals were decreased glomerular filtration rate, hyperkalemia, increased blood creatinine, and dizziness. The adverse events that were concentrated on in investigations were metabolism and nutrition disorders and diseases of the renal and urinary system.</p><p><strong>Conclusions: </strong>Our study identified significant novel adverse events (AEs) signals for finerenone that could provide support for clinical monitoring of and risk identification for finerenone.</p>","PeriodicalId":12232,"journal":{"name":"Expert Opinion on Drug Safety","volume":" ","pages":"1-8"},"PeriodicalIF":3.0000,"publicationDate":"2024-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Opinion on Drug Safety","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14740338.2024.2412218","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: This study analyzed the signal mining of adverse events caused by finerenone based on the US Food and Drug Administration Adverse Event Reporting System (FAERS) and evaluated the drug's safety to provide a reference for the safe administration of this medication in medical institutions.

Methods: FAERS data from the third quarter of 2021 to the fourth quarter of 2023 were used, and the adverse event codes of the Medical Dictionary for Regulatory Activities were compared. After the data were processed, adverse event reports that featured finerenone as the most suspected drug were extracted.

Results: A total of 905 reported cases of adverse events including finerenone as the first suspected drug were extracted. The ratio of male to female patients was 1.25, and most were aged 65-85 years (30.1%). The adverse events that were reported more frequently with positive signals were decreased glomerular filtration rate, hyperkalemia, increased blood creatinine, and dizziness. The adverse events that were concentrated on in investigations were metabolism and nutrition disorders and diseases of the renal and urinary system.

Conclusions: Our study identified significant novel adverse events (AEs) signals for finerenone that could provide support for clinical monitoring of and risk identification for finerenone.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
美国食品药物管理局不良事件报告系统对非格列酮事件的真实世界药物警戒研究。
研究目的该研究基于美国食品药品管理局不良事件报告系统(FAERS),对非格列酮引起的不良事件进行信号挖掘分析,评估该药物的安全性,为医疗机构安全用药提供参考:方法:采用2021年第三季度至2023年第四季度的FAERS数据,对比《监管活动医学词典》中的不良事件代码。数据处理后,提取以非格列酮为最可疑药物的不良事件报告:结果:共提取了 905 例以非格列酮为首要可疑药物的不良事件报告。男性和女性患者的比例为 1.25,大多数患者的年龄在 65-85 岁之间(30.1%)。阳性信号较多的不良事件是肾小球滤过率下降、高钾血症、血肌酐升高和头晕。调查中集中出现的不良事件是代谢和营养失调以及肾脏和泌尿系统疾病:我们的研究发现了非格列酮的重大新不良事件(AEs)信号,可为非格列酮的临床监测和风险识别提供支持。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
5.90
自引率
3.20%
发文量
97
审稿时长
6-12 weeks
期刊介绍: Expert Opinion on Drug Safety ranks #62 of 216 in the Pharmacology & Pharmacy category in the 2008 ISI Journal Citation Reports. Expert Opinion on Drug Safety (ISSN 1474-0338 [print], 1744-764X [electronic]) is a MEDLINE-indexed, peer-reviewed, international journal publishing review articles on all aspects of drug safety and original papers on the clinical implications of drug treatment safety issues, providing expert opinion on the scope for future development.
期刊最新文献
Examining the safety of belimumab, especially in children: an analysis of real-world pharmacovigilance data from the US FDA adverse event reporting system (FAERS) database. Safety concerns of aztreonam: a real-world disproportionality analysis based on FDA adverse event reporting system. Pharmacovigilance insights into drug-induced cystitis: analysis of FDA data from 2004 to 2024. Increased reporting of accidental overdose with glucagon-like peptide-1 receptor agonists: a population-based study. Mining and influencing factors analysis of sacituzumab govitecan adverse drug event based on FAERS database.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1